Cover Image
市場調查報告書

中國的顯影劑市場研究開發預測

Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014

出版商 Huidian Research 商品編碼 296392
出版日期 內容資訊 英文 42 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的顯影劑市場研究開發預測 Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014
出版日期: 2014年01月14日 內容資訊: 英文 42 Pages
簡介

全球整體顯影劑的銷售額在2013年超過230億美元,並以成長率6∼8%持續擴大。

本報告提供全球顯影劑市場發展趨勢,加上中國的顯影劑產業趨勢,各產品區隔趨勢,以及主要企業的競爭環境,進出口資料,企業簡介等彙整資料,為您概述為以下內容。

第1章 顯影劑產業的發展概要

  • 產業的發展
    • 產品的概念
    • 產品的分類
  • 中國的趨勢

第2章 全球顯影劑產業的發展概要

  • 發展趨勢
  • 國際顯影劑專利的申請

第3章 中國的顯影劑產業環境分析

  • 中國的經濟發展環境
  • 政治環境
  • 國內的顯影劑技術層級

第4章 中國的顯影劑產業分析

  • 國內的市場趨勢與預測
  • 各市場區隔產品
    • 加碘鹽類型的產品的注目
    • Ultravist壟斷Iopromide市場
    • 進口及國產的 Iohexol有相等的市場佔有率
    • Iopamidol對Ioversol
    • 國產及海外的釓噴酸葡胺的差異
  • 影響顯影劑的發展的要素
    • 社會經濟的改善
    • 影像診斷·治療設備的廣泛應用
    • 影像診斷治療方法的改善
    • 受診方法的變化

第5章 中國的顯影劑產業的競爭環境

  • 競爭分析
  • 顯影劑產業的集中率

第6章 顯影劑產品的進出口資料

  • X光掃描顯影劑及診斷劑的進出口資料:2010∼2013年
  • X光掃描顯影劑及診斷劑的進口商和外銷處:2013年

第7章 國內的主要的顯影劑製造商

  • Yangtze River Pharmaceutical Group
  • BEILU Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • China Resources Double-crane Pharmaceutical Co., Ltd.
  • Shanghai Xudong Haipu Pharmaceutical Co., Ltd.

第8章 顯影劑產業的投資及發展趨勢

  • 投資的機會
    • 健康意識的提升
    • 醫療治療設備數的增加
  • 投資的風險
  • 中國的顯影劑產業的發展趨勢
    • X光掃描CT顯影劑
    • 核磁共振攝影顯影劑
    • 超音波顯影劑
  • 建議
    • 大企業及特殊化型企業的發展
    • 技術性研究開發的強化
    • 科學性企業經營
    • 品牌認知度
目錄

With the mushroom growth of world diagnostic imaging equipments and apparatuses, as for X-CT contrast media, iodinated contrast media serving as the main one is witnessing unprecedented development. Iohexol is featured with great security, high contrast ratio, lower osmotic pressure and small toxicity for human bodies etc. has become the best-selling contrast media in international market. The sales amount of all kinds of contrast media across the world has exceeded USD 23 billion in 2013, with growth continued to rise at the rate of 6% to 8%.

In recent two years, as for the drug procurement in 22 cities in China, there were six major varieties of contrast media, namely, iohexol, iopromide, gadopentetate dimeglumine, iopamidol, ioversol and meglumine diatrizoate, of which the former three varieties were listed among the best-selling 200 drugs. Recently, hospitals attached more importance to instrument testing, boosting the development of contrast media market.

According to the procurement of contrast media from sampled hospitals in 16 cities, iohexol and iopromide rank first and second respectively, accounting for 43% and 32% of market shares of CT contrast media respectively in domestic market. As for domestic MRI contrast media, gadopentetate dimeglumine still plays the leading role, accounting for 83% of market shares of MRI contrast media.

At present, Bayer Health Care, GE, Shanghai Bracco Sine Pharmaceutical Corp. Ltd., Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Ltd. and BEILU Pharmaceutical Co., Ltd. dominate domestic contrast media market, they account for over 80% of market shares totally.

In recent two years, domestic hospitals with certain strength put their attention on testing and examining, so they increased investment in imaging equipments, resulting in bringing momentum for the growth of contrast media market. Competition in contrast media market is not too fierce, and overall the market is on the rising trend. With continuous input and perfection of inspection equipments in China's large-scale hospitals, contrast media market will continue go up. In addition, contrast media price is high in terms of retail sales with considerable profits, representing one of motivators for its rapid growth. It is predicted that in the next five years, with people's rising health awareness and increase of medical facilities, domestic contrast media market will maintain stable growth, with annual growth rate registering 20%.

Table of Contents

1. Development Overview of Contrast Media Industry

  • 1.1. Overview of Industry

1.1.1Product Concept

    • 1.1.2. Product Classification
  • 1.2. Industry China

2. Development Overview of Global Contrast Media Industry

  • 2.1. Development Status
  • 2.2. Application for International Contrast Media Patents

3. Environment Analysis of China's Contrast Media Industry

  • 3.1. China's Economic Development Environment
  • 3.2. Policy Environment
    • 3.2.1. National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance Drug Catalogue
    • 3.2.2. Suggestions on Consolidating Essential Medicine System and New Operation Mechanism of Grass Roots
  • 3.3. Domestic Technological Level of Contrast Media
    • 3.3.1. Technical Status
    • 3.3.2. Patent Application in China

4. Analysis on China's Contrast Media Industry

  • 4.1. Domestic Market Status and Forecast
  • 4.2. Segment Products
    • 4.2.1. Much Attention on Iodized Salt Type of Products
    • 4.2.2. Ultravist Dominates Iopromide Market
    • 4.2.3. Imported and Domestic Iohexol Have Equal Shares
    • 4.2.4. Iopamidol vs. Ioversol
    • 4.2.5. Differences between Domestic and Overseas Gadopentetate Dimeglumine
  • 4.3. Factors Affecting Contrast Media Development
    • 4.3.1. Improvement of Social Economy
    • 4.3.2. Wide Application of Imaging Diagnostic and Treatment Equipment
    • 4.3.3. Improvement of Imaging Diagnostic and Treatment Method
    • 4.3.4. Changes of Seeing a Doctor

5. Competitive Landscape of China's Contrast Media Industry

  • 5.1. Competitiveness Analysis
    • 5.1.1. Upstream Bargaining Power
    • 5.1.2. Periodic Fluctuation of Consumers' Bargaining Power
    • 5.1.3. Potential Entrant
    • 5.1.4. Competition in the Industry
  • 5.2. Concentration Ratio of Contrast Media Industry
    • 5.2.1. Concentration Ratio of China's CT Contrast Media Market
    • 5.2.2. Concentration Ratio of China's MRI (Magnetic Resonance Imaging) Contrast Media Market

6. Import and Export Data of Contrast Media Products

  • 6.1. Import and Export Data of X-Ray Contrast Media and Diagnostic Reagent, 2010-2013
  • 6.2. Import Sources and Export Destinations of X-Ray Contrast Media and Diagnostic Reagent, 2013

7. Domestic Major Contrast Media Manufacturing Enterprises

  • 7.1. Yangtze River Pharmaceutical Group
    • 7.1.1. Company Profile
    • 7.1.2. Main Business
    • 7.1.3. Competitive Edge
    • 7.1.4. Business Performance
    • 7.1.5. Future Development Strategy
  • 7.2. BEILU Pharmaceutical Co., Ltd.
    • 7.2.1. Company Profile
    • 7.2.2. Main Business
    • 7.2.3. Competitive Edge
    • 7.2.4. Business Performance
    • 7.2.5. Future Development Strategy
  • 7.3. Jiangsu Hengrui Medicine Co., Ltd.
    • 7.3.1. Company Profile
    • 7.3.2. Main Business
    • 7.3.3. Competitive Edge
    • 7.3.4. Business Performance
    • 7.3.5. Future Development Strategy
  • 7.4. China Resources Double-crane Pharmaceutical Co., Ltd.
    • 7.4.1. Company Profile
    • 7.4.2. Main Business
    • 7.4.3. Competitive Edge
    • 7.4.4. Business Performance
    • 7.4.5. Market Structure of Cardiac Ultrasound Contrast Media
  • 7.5. Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
    • 7.5.1. Company Profile
    • 7.5.2. Main Business
    • 7.5.3. Product Performance

8. Investment and Development Trend of Contrast Media Industry

  • 8.1. Investment Opportunities
    • 8.1.1. Rising Health Consciousness
    • 8.1.2. Increasing Number of Medical Treatment Equipment (MRI Equipment)
  • 8.2. Investment Risks
  • 8.3. Development Trend of China's Contrast Media Industry
    • 8.3.1. X-Ray CT Contrast Media
    • 8.3.2. MRI Contrast Media
    • 8.3.3. Ultrasound Contrast Media
  • 8.4. Suggestions
    • 8.4.1. Large-Scale and Specialized Enterprise Development
    • 8.4.2. Strengthen Technology R&D
    • 8.4.3. Scientific Enterprise Management
    • 8.4.4. Build Brand Awareness
Back to Top